Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

A. Davies, A. K. Gopal, B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jurczak, I. W. Flinn, C. R. Flowers, R. Dansey, P. Martin, A. Viardot, K. A. Blum, A. H. Goy, J. Gribben, H-T Arkenau, R. Johnson, K. Linton, P. L. Zinzani, M. DreylingG. A. Salles

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article number3
Pages (from-to)2
Number of pages1
JournalBritish Journal of Haematology
Issue numberS1
Early online date28 Apr 2014
Publication statusPublished - May 2014

Cite this